Novartis Hopes To Breathe New Life Into CAR-T Business With ASCO Myeloma Data

Gilead’s Kite has taken a lead in multiple myeloma cell therapy while Novartis’s first-to-market Kymriah has slumped in sales, but the Swiss drug maker’s new data may support its effort to win on manufacturing time.

Novartis and Gilead's Kite Pharma at ASCO • Source: Alaric DeArment

Novartis AG bears the distinction of being the first to market with a cell therapy, the CAR-T Kymriah (tisagenlecleucel), which won US Food and Drug Administration approval in August 2017 for acute lymphoblastic leukemia (ALL) in children, followed by diffuse large B-cell lymphoma (DLBCL) for adults the next year. But since then, it has fallen behind the second CAR-T to win approval, Gilead Sciences, Inc.’s Yescarta (axicabtagene ciloleucel). Now, Novartis is hoping to regain a leading role in the cell therapy space with new data in multiple myeloma at the American Society of Clinical Oncology meeting.

Both companies presented data for their CAR-Ts at ASCO in early June, including Gilead presentations on Yescarta and its sister...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from ASCO

More from Conferences